Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination With CEA Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or GM-CSF In HLA-A2+ Patients With CEA Producing GI Adenocarcinomas
NCT00012246Phase 2Terminated
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Jul 2002
- Primary completion
- Jul 2006
- Modality
- Prophylactic Vaccines, Peptides, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised trial of CEA peptide 1-6D in gastrointestinal adenocarcinoma (GIAC) (2 arms), sponsored by The University of Texas Medical Branch at Galveston. Primary endpoints: Production of CAP 1-6D T cells, Production of cytotoxic T cells and 2 more. Started Jul 2002; status: terminated.
02
Drugs
CEA peptide 1-6D
03
Conditions
gastrointestinal adenocarcinoma (GIAC)
Beyond the preview
Go deeper on NCT00012246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012246.